Objective: To study the relationship between gray matter atrophy and amyloid deposition in Alzheimer disease (AD).
The relationship between brain atrophy and amyloid deposition in Alzheimer disease (AD) has implications on current clinical trials with antiamyloid drugs. Atrophy is a valid disease marker in AD, and brain atrophy is currently a widely used surrogate outcome in current phase III clinical trials of drugs that might delay or arrest AD progression. 1 Most current diseasemodifying drugs for AD have been developed under the assumption that cognitive deterioration is due to amyloid deposition and that slowing or arresting amyloid deposition will lead to slowing or arresting cognitive deterioration. 2 The recent availability of in vivo PET ligands for amyloid such as [ 11 C]-PIB, i.e., 2-[4=-(methylamino)phenyl]-6-hydroxybenzothiazole, has led to the possibility of studying the relationship between brain atrophy and amyloid deposition directly and in vivo, the prediction being that regions with greater atrophy would also be those with greater amyloid deposition. This has been found not to be the case, because the first patients with AD scanned with [ 11 C]-PIB showed the largest amount of uptake in the frontal cortex, 3 an area where the disease is believed to strike relatively later in the course, and, consequently, atrophy is believed to occur relatively late. A later study investigating the relationship of prospective percentage tissue loss with tracer uptake seemed to somehow reconcile the contrasting findings in that faster tissue loss before amyloid imaging was reportedly associated with greater amyloid burden. 4 Recently, the toxicity of brain amyloid deposition was again questioned by showing that faster rates of tissue loss were not correlated with pathologically confirmed greater amyloid burden but rather with more severe Braak neurofibrillary tangle stage. 5 The aim of the present study is to assess the relationship between gray matter (GM) atrophy and amyloid deposition in AD by mapping the match and mismatch of the two phenomena. Magnetic resonance (MR)based structural images were collected at the time of [ 11 C]-PIB PET images in 23 patients and 17 controls, coregistered, and studied with voxel-based methods.
METHODS Subjects. The [ 11 C]-PIB uptake results of the majority of the subjects of this study have been previously described. 6 Patients (table 1) were diagnosed with probable AD according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria, had progressive disease with impairment of memory and at least one additional cognitive domain, and were assessed using a comprehensive neuropsychological test battery that included Consortium to Establish a Registry for Alzheimer's Disease, Wechsler Memory Scale-Revised, parts of Wechsler Adult Intelligence Scale-Revised, Trail Making Test, Stroop, Alzheimer's Disease Assessment Scale-Cognitive subscale, clock drawing, Rey figure copy, digit span forward, Boston Naming Test, and word fluency. The tests showed typical impairment in memory functions and in at least one separate cognitive function compared with age-appropriate norms and estimated premorbid levels (data not shown).
Seventeen healthy volunteers with no history of neurologic or psychiatric disease, with no medications affecting the CNS, and with normal brain MR scans were studied as a control group. The study was approved by the Ethical Committee of Southwest Finland Health Care District, and both patients and healthy volunteers gave informed consent to perform the study.
Image acquisition. [ 11 C]-PIB PET scanning protocol.
Radiochemistry details have been previously provided. 6 All subjects underwent a 90-minute dynamic PET scan with a GE Advance PET scanner (GE Medical Systems, Milwaukee, WI) in the three-dimensional scanning mode (septa retracted) providing 35 slices of 4.25-mm thickness covering the whole brain. The spatial resolution (full-width at half-maximum) of the camera is 4.3 mm transaxially and 4.3 mm axially. Laser light beams were used in head positioning according to the orbitomeatal and sagittal lines. Before the injection of the radiotracer, an 8-minute transmission scan with 68Ge rod sources was performed for attenuation correction. [ 11 C]-PIB was then injected into an antecubital vein as a bolus with a mean dose of 414 MBq (SD 103) and flushed with saline. The frame sequence of the scan consisted of four 30-second frames, nine 1-minute frames, three 3-minute frames, ten 5-minute frames, and two 10-minute frames. No blood sampling was performed during the scan. Imaging data were reconstructed into a 128 ϫ 128 matrix using a transaxial Hann filter with a 4.6-mm cutoff and an axial ramp filter with an 8.5-mm cutoff.
MRI acquisition protocol. At the time of PET scanning, all subjects also underwent MRI scan with a Philips Gyroscan Intera 1.5-T CV Nova Dual scanner (Philips Medical Systems, Best, The Netherlands). This included axial T2-weighted spinecho images, coronal fluid-attenuated inversion recovery images, and axial T1-weighted three-dimensional (repetition time 25 msec, echo time 5 msec, slice thickness 1 mm) with a 512 ϫ 512 or 256 ϫ 256 matrix and 1 excitation.
Image processing. PIB voxel-based imaging. We flipped parametric [ 11 C]-PIB images to neurologic convention using MRIcro software 7 (MRIcro, http://www.sph.sc.edu/comd/ rorden/mricro.html), and we resampled voxel size to 2 ϫ 2 ϫ 2 with SPM2 (Statistical Parametric Mapping, version 2, http:// www.fil.ion.ucl.ac.uk/spm/software/spm2). We coregistered [ 11 C]-PIB to the pertinent MR images after BET 8 scalp removal. We then created a [ 11 C]-PIB customized template through 1) coregistration and affine normalization of the [ 11 C]-PIB images to the respective MR images; 2) linear plus nonlinear spatial normalization of images from 1) using parameters determined from the normalization of MR images to the MR template; and 3) creation of the mean image from 2) and averaging with its mirror copy to ensure the symmetry. We processed all coregistered [ 11 C]-PIB scans with SPM2 according to an optimized processing protocol previously developed and validated for SPECT and fluorodeoxyglucose (FDG) PET images, and described in detail elsewhere. 9 MR voxel-based imaging. Because of differences in acquisition matrix size (either 512 ϫ 512 or 256 ϫ 256), we first resampled all MR images to 256 ϫ 256 size using a specific tool developed at the Montreal Neurological Institute (MNI, mincresample, http://www.bic.mni.mcgill.ca/software). We then scaled all images to the same intensity range (0 -100), flipped them in neurologic convention using MRIcro, and processed them with SPM2 following a standard voxel-based morphometry procedure described in detail elsewhere. 10, 11 We computed a customized template and customized prior probability maps for GM, white matter, and CSF from the whole sample. 12 MR images were then normalized to the customized template through affine and nonlinear transformations; were segmented into GM, white matter, and CSF using the customized priors masked to remove non-brain tissue voxels; were modulated; and finally were smoothed with a 12-mm isotropic gaussian kernel. 10, 11 Only GM images were further used in the statistical analysis.
Region-of-interest analyses. We chose several regions of interest (ROIs) relevant to AD, located in the frontal and temporal lobes, posterior cingulate/retrosplenial region, insula, caudate, and amygdala, from the WFU Pickatlas, 13 available as a SPM2 toolbox. Because these regions relate to the SPM2 MNI_T1 template, we normalized the latter to our customized template, and we applied the transformation parameters to all ROIs to make these suitable to our maps. The hippocampal mask was defined according to a procedure derived by Mosconi et al. 14 
All
ROIs used in this study are available at www.centroalzheimer.it/ public/ROIs_paper.doc.
Statistical analysis. Group difference analysis. We used the "single subject: conditions and covariates" SPM2 model to assess, on a voxel-by-voxel basis, where [ 11 C]-PIB uptake in AD is greater than in normal controls. Statistical comparison was performed setting the one-tailed significance threshold at 0.05 corrected for family-wise error (FWE). We also tested also the opposite comparison, but with no significant finding.
We then used the same "single subject: conditions and covariates" SPM2 model on segmented GM images to assess whether GM density in normal controls is greater than in patients with AD. Total intracranial volume was entered as a confounding variable.
Again, the opposite comparison was also tested with no significant finding.
Correlation analysis. Two different approaches were used to investigate the correlation between atrophy and PIB uptake. Because native [ 11 C]-PIB scans were coregistered to their respective MR images and the study-specific [ 11 C]-PIB template was coregistered to the high-definition MR template, all the normalized [ 11 C]-PIB and MR images used for the statistical analysis were coregistered to the SPM standard anatomic space so that [ 11 C]-PIB uptake and atrophy patterns could be compared on a voxel-by-voxel basis.
The Pearson r coefficient was computed voxel-wise, and a whole brain correlation map was created, using a Matlab script written specifically for this purpose. Linear relationship between variables was assumed, and intensity normal distribution was checked on ROI mean values. Voxel-by-voxel significance of the Pearson r correlation map was computed using Matlab, and the significance threshold was set at p Ͻ 0.001 uncorrected.
We computed mean GM intensities and PIB uptake regionto-cerebellar ratio values within each ROI for all patients with AD and normal controls, and we then compared these values between the two groups through a t test. We finally investigated the correlation between atrophy and PIB uptake and the related highest in the frontal and lowest in the caudate and hippocampal ROIs. Figure 2 shows that the areas with significant lower GM density corresponding to greater [ 11 C]-PIB uptake were located in the medial temporal regions, a few small scattered spots being present also in neocortical areas. These included the lateral temporal, parietal, posterior cingulate, and frontal cortex. Figure 3 shows the same effect at the ROI level: despite that [ 11 C]-PIB uptake in the hippocampus is lower (between 1.0 and 1.6) than in most other regions of the brain (up to 2.25 in the posterior cingulate/retrosplenial cortex), here the reduction in GM density ties in with the amount of [ 11 C]-PIB uptake (r ϭ Ϫ0.54, p Ͻ 0.001). In the other areas, this result is significant only in the amygdala (r ϭ Ϫ0.40), whereas it is not significant in the frontal, temporal, posterior cingulate/retrosplenial, insular, and caudate ROIs. The point estimate of the slope of the relationship between hippocampal GM density and [ 11 C]-PIB uptake is significantly different from zero (B ϭ Ϫ0.15, 95% confidence interval Ϫ0.23 to Ϫ0.07; figure 3, hippocampus). When the relationship was assessed in the smaller group of patients with AD, the point estimate of the slope was still negative, although not significantly different from zero (B ϭ Ϫ0.05, 95% confidence interval Ϫ0.14 to 0.05).
DISCUSSION
In this study, we have studied in vivo the local toxicity on the GM of amyloid deposition, toxicity being indexed by atrophy on MRI and amyloid deposition by [ 11 C]-PIB uptake on PET. We have found that greater amyloid deposition was generally not associated with more severe GM atrophy except in the medial temporal lobes (amygdalae and hippocampi), where greater amyloid deposition was associated with lower GM density. The medial temporal lobe was among the regions with the lowest amount of amyloid deposition, indicating that different types of amyloid may deposit in the brain, that different brain regions may be differentially susceptible to its toxic effects, or that amyloid is peripheral to neurodegeneration.
The relative amount and topography of [ 11 C]-PIB uptake that we found in the present study as well as the topography of brain atrophy are consistent with available literature. [ 11 C]-PIB uptake is highest in the frontal lobe and milder in the medial temporal lobe, 15 possibly because of greater deposition of tangles relative to amyloid. 16, 17 In late-onset AD, brain atrophy is more severe in the medial temporal and posterior cingulate/retrosplenial region and relatively milder in neocortical frontal, temporal, parietal, and occipital regions. 18, 19 A recent study has found that Signal intensities are averaged between right and left regions of interest. Effect size is computed as: Cohen d: (Mean 1 -Mean 2 )/sqrt((SD 1 2 ϩ SD 2 2 )/2). AD ϭ Alzheimer disease. atrophy and [ 11 C]-PIB uptake independently contribute to discriminating patients with AD, patients with amnestic MCI, and healthy elders. 20 Although these results are in agreement with those of the present study, the topographic relationship of the two phenomena was not explicitly addressed, which we did in the present study.
The local association of amyloid load and atrophy in the medial temporal lobe is in agreement with pathologic data indicating that amyloid load in the medial temporal lobe correlates with cognitive performance. Although the largest body of literature indicates that the strongest correlates of cognitive impairment are neuronal counts and neurofibrillary tangles in the medial temporal lobe and neocortex, 21 accurate estimates of amyloid burden have shown that the assessment of the total volume occupied by the amyloid deposits in the entorhinal cortex and subiculum can be considered an effective predictor of dementia severity. 22 Others, however, claim that the effect of fibrillar amyloid deposits on cognition is indirect because it disappears when adjusting for total tangle numbers in this area, 23 which we could not control for in the present study. The finding of a postmortem study that a decrease in spinophilin immunoreactivity (a marker of synaptic integrity) was significantly related to both Braak neurofibrillary tangle staging and clinical severity but not amyloid deposition staging is in agreement with the dissociation found between neuronal loss (atrophy) and amyloid load ([ 11 C]-PIB uptake) in our study. 24 At least two hypotheses can be proposed to explain the topographic mismatch between [ 11 C]-PIB uptake and atrophy.
The hypothesis of differential susceptibility to amyloid is supported by findings of a pathologic study of 17 subjects in the severe stage of AD where numerical densities of neurons with neurofibrillary tangles correlated with the densities of thioflavin-Spositive fibrillar plaques with neurofibrillary changes, indicating that neurofibrillary pathology in neocortical plaques reflects the topography of neurofibrillary changes in neocortical neurons. 25 In line with in vitro evidence that tau is essential to ␤-amyloid-induced neurotoxicity, 26 the authors conclude that fibrillar ␤-amyloid affects neurofibrillary changes only in neurons already involved in neurofibrillary degeneration. Because neurofibrillary degeneration occurs early in the disease course and is particularly severe in the medial temporal structures and relatively milder in the neocortex, this observation might represent the pathophysiologic basis of the greater susceptibility of medial temporal structures to the toxic effects of ␤-amyloid.
Regional differences of the toxic effect of amyloid load have been recently reported by two com-
Figure 2
Correlation between gray matter and [ 11 C]-PIB uptake in 23 patients with Alzheimer disease and 17 normal controls
The correlation is highest and most significant in the medial temporal region and in a few scattered spots in the neocortex, including the posterior cingulate cortex. The colored bars denote Pearson r and Student t with 32 degrees of freedom (significance threshold set at p Ͻ 0.001 uncorrected).
bined [ 11 C]-PIB and [ 18 F]-FDG PET studies 27, 28 in patients with probable AD and healthy controls showing that increased amyloid load in temporoparietal regions and the cingulate gyrus was associated with lower glucose use in these same areas, whereas larger loads of amyloid in the frontal lobes, striatum, and thalamus were not coupled with similar metabolic decreases. 27, 28 These data support the idea that amyloid plaques exert nonuniform effects across different brain areas. Alternatively, insoluble ␤-amyloid might be a downstream marker of local cell death, but amyloid imaging cannot test which hypothesis is correct.
The differential susceptibility hypothesis invokes the old question of what molecular mechanisms are behind the selective vulnerability (pathoclisis) of different brain areas in neurodegenerative diseases. 29, 30 It has been suggested that brain areas with lower basal or default activity on fMRI and greater taskspecific activity are more resistant, whereas brain regions with high basal activity, such as the poste-rior cingulate/retrosplenial, temporoparietal, and cingulate cortex, are more prone to ␤-amyloid deposition. 31 Whether [ 11 C]-PIB binds to different types of amyloid with different toxicity is a more speculative argument. Evidence is accumulating that [ 11 C]-PIB binds to extracellular plaques as well as vascular amyloid, 32,33 and biochemical differences have been described between plaque and vascular amyloid regarding associated hydrophobic amyloid variants 34 that might differentially bind to [ 11 C]-PIB. However, the molecular features of the binding of [ 11 C]-PIB to different ␤-amyloid types such as A␤40 and A␤42 that are differentially distributed in parenchymal plaques and vascular amyloid are only partly known. 35 Of course, it is also possible to regard the modest relationship between brain atrophy and brain amyloidosis that we found as indicative that neither of the previous two hypotheses are true, but rather that PIB-positive amyloidosis is peripheral to brain degeneration. Indeed, the so far dominant amyloid hy- pothesis of AD has lately been shaken by a number of observations coming from failed clinical trials of antiamyloid drugs 36, 37 and pathologic data from the original AN1792 vaccine trial. 38 Moreover, a recent [ 11 C]-PIB PET imaging study has found that approximately one-fifth of cognitively unimpaired older persons can be categorized as PIB positive in at least one brain region. 39 However, we believe that the overwhelming evidence on familial AD cases due to mutations of enzymes involved in amyloid metabolism provide still unfalsified backing to the amyloid hypothesis of AD. Any purely nonamyloid hypothesis is therefore at least as incomplete. Some limitations should be taken into account in the interpretation of the present results. First, our controls were approximately 7 years younger than patients. Although this might have inflated the structural and functional image differences between the two groups, it can hardly account for the differential topography of the relationship between atrophy and [ 11 C]-PIB uptake. Second, we did not perform partial volume effect correction for our data. In small atrophied structures such as the hippocampus, partial volume effect could result in weaker signal because of inclusion of surrounding CSF in the ROI. Last, in the present study we have studied the correlation between [ 11 C]-PIB and atrophy by pooling healthy persons and patients with AD, and we cannot exclude that intergroup differences in both hippocampal volume and [ 11 C]-PIB uptake might have driven the correlation results. Future work with larger study groups will need to confirm the relationships we found only in patients with AD.
